Alamar Biosciences, Inc.
For the period ended Jun 30, 2026. Filed Aug 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 11, 2026
ALMR$31.50-1.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(Unaudited, in thousands)
| Six Months Ended June 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities: | ||
| Net loss | $(34,524) | $(14,682) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization expense | 2,301 | 1,807 |
| Stock-based compensation | 4,747 | 1,299 |
| Accretion and amortization of premiums and discounts on investments, net | (137) | (222) |
| Loss on remeasurement of convertible notes | 9,971 | — |
| Convertible note issuance costs included in net loss | 361 | — |
| Unrealized foreign exchange loss (gain) | 245 | (527) |
| Non-cash operating lease costs | 1,145 | 867 |
| Amortization of debt issuance costs | 137 | 86 |
| Change in fair value of warrant liabilities | 117 | 23 |
| Provision for expected credit losses | 135 | — |
| Changes in assets and liabilities: | ||
| Accounts receivable | (7,821) | (2,849) |
| Inventory | (6,990) | (9,418) |
| Contract assets | — | 413 |
| Net investment in sales-type lease | — | 173 |
| Prepaid expenses and other current assets | (2,860) | 349 |
| Other noncurrent assets | (811) | 120 |
| Accounts payable | 7,658 | (1,235) |
| Operating lease liabilities | (903) | (955) |
| Accrued expenses and other liabilities | (4,440) | (199) |
| Net cash used in operating activities | (31,669) | (24,950) |
| Cash flows from investing activities: | ||
| Purchases of short-term investments | (117,045) | (4,940) |
| Maturities of short-term investments | — | 42,000 |
| Purchases of property and equipment | (4,242) | (1,307) |
| Capitalized software development costs | (287) | (790) |
| Net cash (used in) provided by investing activities | (121,574) | 34,963 |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock in connection with IPO, net of underwriting costs | 204,542 | — |
| Payment of third-party IPO costs | (6,150) | — |
| Proceeds from issuance of convertible notes | 56,500 | — |
| Payment of third-party debt issuance costs | (324) | — |
| Proceeds from issuance of common stock upon exercise of stock options | 3,034 | 407 |
| Net cash provided by financing activities | 257,602 | 407 |
| Effect of exchange rate changes on cash and cash equivalents, and restricted cash | (45) | 469 |
| Net increase in cash, cash equivalents and restricted cash | 104,314 | 10,889 |
| Cash, cash equivalents and restricted cash at beginning of period | 34,909 | 31,677 |
| Cash, cash equivalents and restricted cash at end of period | $139,223 | $42,566 |
| Supplemental disclosure of cash-flow information: | ||
| Cash paid for interest | $303 | $6 |
| Noncash investing and financing items: | ||
| Conversion of convertible preferred stock to common stock | $234,996 | $— |
| Conversion of convertible notes to common stock | $66,471 | $— |
| Reclassification of deferred offering costs to additional paid-in capital upon IPO | $6,705 | $— |
| Vesting of early exercised stock options | $230 | $9 |
| Right-of-use assets obtained in exchange for new operating lease liabilities | $10,807 | $134 |
| Conversion of preferred stock warrants to common stock warrants | $364 | $— |
| Equipment transferred to inventory | $10 | $169 |
| Property and equipment included in accounts payable and accrued liabilities | $601 | $196 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.